Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02546661
Title Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AstraZeneca
Indications

invasive bladder transitional cell carcinoma

Therapies

AZD9150 + Durvalumab

Durvalumab + Selumetinib

AZD4547

Durvalumab + Olaparib

Durvalumab

AZD4547 + Durvalumab

Durvalumab + Vistusertib

Adavosertib + Durvalumab

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST